These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Kühne T; Imbach P Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290 [TBL] [Abstract][Full Text] [Related]
3. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Garnock-Jones KP Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480 [TBL] [Abstract][Full Text] [Related]
4. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973 [TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925 [TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. Atkinson K Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797 [TBL] [Abstract][Full Text] [Related]
7. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Zhang Y; Kolesar JM Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810 [TBL] [Abstract][Full Text] [Related]
8. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608 [TBL] [Abstract][Full Text] [Related]
10. Sustaining platelet counts in chronic ITP. Nurden AT Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056 [No Abstract] [Full Text] [Related]
11. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center. González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127 [No Abstract] [Full Text] [Related]
12. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review. Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713 [TBL] [Abstract][Full Text] [Related]
13. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Stasi R; Evangelista ML; Amadori S Drugs; 2008; 68(7):901-12. PubMed ID: 18457458 [TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era. Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624 [TBL] [Abstract][Full Text] [Related]
15. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia. Panzer S Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229 [TBL] [Abstract][Full Text] [Related]
16. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics. Meyer O; Salama A Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379 [TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF; Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461 [TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
19. [Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan]. Yoshida M; Kanashima H; Nakao T; Ogawa Y; Hino M; Nakane T; Ohta T; Kumura T; Manabe M; Yamamura R; Yamane T Rinsho Ketsueki; 2013 May; 54(5):444-50. PubMed ID: 23727682 [TBL] [Abstract][Full Text] [Related]